• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Estimating the potential effects of a vaccine program against an emerging influenza pandemic-United States

tetano

Editor, Senior Moderator
Clin Infect Dis. 2015 May 1;60 Suppl 1:S20-9. doi: 10.1093/cid/ciu1175.
[h=1]Estimating the potential effects of a vaccine program against an emerging influenza pandemic-United States.[/h] Biggerstaff M[SUP]1[/SUP], Reed C[SUP]1[/SUP], Swerdlow DL[SUP]2[/SUP], Gambhir M[SUP]3[/SUP], Graitcer S[SUP]4[/SUP], Finelli L[SUP]1[/SUP], Borse RH[SUP]5[/SUP], Rasmussen SA[SUP]6[/SUP], Meltzer MI[SUP]5[/SUP], Bridges CB[SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Human illness from influenza A(H7N9) was identified in March 2013, and candidate vaccine viruses were soon developed. To understand factors that may impact influenza vaccination programs, we developed a model to evaluate hospitalizations and deaths averted considering various scenarios.
[h=4]METHODS:[/h] We utilized a model incorporating epidemic curves with clinical attack rates of 20% or 30% in a single wave of illness, case hospitalization ratios of 0.5% or 4.2%, and case fatality ratios of 0.08% or 0.53%. We considered scenarios that achieved 80% vaccination coverage, various starts of vaccination programs (16 or 8 weeks before, the same week of, or 8 or 16 weeks after start of pandemic), an administration rate of 10 or 30 million doses per week (the latter rate is an untested assumption), and 2 levels of vaccine effectiveness (2 doses of vaccine required; either 62% or 80% effective for persons aged <60 years, and either 43% or 60% effective for persons aged ≥60 years).
[h=4]RESULTS:[/h] The start date of vaccination campaigns most influenced impact; 141 000-2 200 000 hospitalizations and 11 000-281 000 deaths were averted when campaigns started before a pandemic, and <100-1 300 000 hospitalizations and 0-165 000 deaths were averted for programs beginning the same time as or after the introduction of the pandemic virus. The rate of vaccine administration and vaccine effectiveness did not influence campaign impact as much as timing of the start of campaign.
[h=4]CONCLUSIONS:[/h] Our findings suggest that efforts to improve the timeliness of vaccine production will provide the greatest impacts for future pandemic vaccination programs.
Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.


[h=4]KEYWORDS:[/h] influenza; influenza A(H7N9); influenza vaccine; mathematical modeling; pandemic

PMID: 25878298 [PubMed - in process]
 
Back
Top Bottom